Radiotherapy solutions company CIVCO Radiotherapy and POLL Medical on Thursday jointly announced the receipt of US Food and Drug Administration (FDA) 510(k) clearance to market GrayDuck Stents.
The new product provides custom oral positioning with repeatable tongue deviation during radiotherapy.
GrayDuck Stents are designed to improve patient treatment and outcomes by sparing the tongue, taste buds and salivary glands from unnecessary dose. The stent can position the tongue in one of several positions: laterally (left or right), depressing (downward) or a combination thereof.
According to the company's director John Steffen, the ability to offer a custom device that can be formed in less than 15 minutes is very meaningful for the patient and clinical workflow, while still providing high quality positioning necessary for treatment.
GrayDuck stents were issued the US Patent 9,504,537 with additional patents pending worldwide. The stents are available in Europe with CE Mark and now in the US with FDA 510(k) clearance.
Aetna to launch generative AI-powered conversational experience
Maxx Orthopedics Receives FDA 510(k) Clearance for Its Libertas® Bipolar Hip System
Ascletis Pharma announces ASC36 and ASC35 co-formulation for clinical development
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies
Nurami Medical completes Phase 1 milestones in EIC-backed grant for Artifix
Organon to sell JADA System to Laborie for up to USD465m
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
BD launches IVDR-certified self-collection solution to expand global access to HPV testing
Oticon launches Oticon Zeal, a discreet, fully featured in-the-ear hearing aid
Halozyme Therapeutics announces Q3 2025 release date
Samsung to invest USD110m in GRAIL and commercialise cancer detection test Galleri in Asia
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025